BACKGROUND Proton pump inhibitors and histamine H2 receptor antagonists are two of the most commonly prescribed drug classes for pediatric gastroesophageal reflux disease, but their efficacy is controversial. Many patients are treated with these drugs for atypical manifestations attributed to gastroesophageal reflux, even that causal relation is not proven. OBJECTIVE To evaluate the use of pr...

The association between use of proton pump inhibitors and risk of hip fracture was investigated in postmenopausal women. Women who were enrolled in the Nurses’ Health Study, a prospective cohort study, provided data biennially from 2000 until June 2008. The primary outcome was time until first hip fracture. The incidence rate of hip fracture was higher among regular users of proton pump inhibit...

OBJECTIVE To examine the relation between the type of stress ulcer prophylaxis administered and the risk of postoperative pneumonia in patients undergoing coronary artery bypass grafting. DESIGN Retrospective cohort study. SETTING Premier Research Database. PARTICIPANTS 21,214 patients undergoing coronary artery bypass graft surgery between 2004 and 2010; 9830 (46.3%) started proton pump ...

Esomeprazole, the S-isomer of omeprazole was developed with the aim of improving the pharmacokinetic and pharmacodynamic profiles of racemic omeprazole [1]. It suppresses the secretion of hydrochloric acid from gastric parietal cells via inhibition of the H+/K+ adenosine triphosphatase enzyme like other proton pump inhibitors [2]. Among all proton pump inhibitors available, esomeprazole is the ...

E vidence is accumulating in relation to adverse events associated with proton pump inhibitors (PPIs). Reports in the Archives have demonstrated an association with fractures, Clostridium difficile infections, and community-acquired pneumonia. Proton pump inhibitors may also attenuate the antiplatelet benefits of clopidogrel. Because frail older people often use PPIs and may be especially vulne...

Acid inhibitory therapy has long been considered of no benefit for upper GI bleeding. The reason was that achlorhydria in the stomach could not be achieved with any single or combination of acid inhibitory drugs. The introduction of proton pump inhibitors has, for the first time, allowed the physician to temporarily achieve achlorhydria by large doses of intravenously applied proton pump inhibi...

BACKGROUND The administration of proton pump inhibitors intravenously after endoscopic treatment of peptic ulcers significantly reduces the recurrence of bleeding. AIM To evaluate the incremental cost-effectiveness in Canada of intravenous proton pump inhibitor before endoscopic therapy to patients presenting with acute upper gastrointestinal bleeding, compared with endoscopic treatment alone...